Inhibition of immune checkpoint proteins, including PD-1, PD-L1, CTLA-4 represent a significant breakthrough in the cancer immunotherapy, showing notable success in treating patients with melanoma, renal cell carcinoma, head and neck cancers or non-small-cell lung cancer [12,13,14,15]. This evidence concerns the gene CD274 and cancer.